Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol, Version 6, 08 Jul 2020, MHRA
Table of Contents
Page Number(s):
D. Arrangements for notification
E. Identifying serious breaches
G. Organisation Responsibilities
Appendix I - Expectations for Specific Serious Breach Topics
Appendix II Examples of Serious Breaches Notified to MHRA (this is not an exhaustive list)
Source: Medicines & Healthcare products Regulatory Agency, the UK.
Clinical Research News
Připravované klinické studie
-
NCT05891834Zatím nenabírámeObezita | Metabolický syndrom
-
NCT05893381Zatím nenabíráme
-
NCT05892874Nábor
-
NCT05891574Zatím nenabíráme
-
NCT05892744Zatím nenabírámeVelká depresivní porucha | Chronická velká deprese, opakující se
-
NCT05892640Nábor
-
NCT05891444NáborAlzheimerova nemoc | Elektroencefalografie | Transkraniální náhodný šum
-
NCT05892328NáborKardiovaskulární choroby | Pre-hypertenze
-
NCT05892718Zatím nenabírámePokročilý pevný nádor | Refrakterní non-Hodgkinův lymfom
-
NCT05893199Zatím nenabíráme
Clinical Research Jobs
-
CRA (Level II) - Paris - Home-based
-
Clin Ops Delivery Associate I
-
Site Alliance Manager
-
eClinical Business Lead - Poland, Romania, Italy, Spain, Hungary, Lithuania
-
Senior Clinical Research Associate - Paris (FSP)
-
Clinical Trial Payments Coordinator (FSP) Warsaw
-
Senior Clinical Research Associate (FSP) - Warsaw
-
Project Manager - Early Phase Clinical Operations
-
Senior Regulatory Affairs Associate
-
Senior Associate - Clinical Outcomes Assessment
-
IRT Specialist
-
Site Intelligence Specialist (FSP)